Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule

Shamez Ladhani; Nicholas Andrews; Pauline Waight; Bassam Hallis; Mary Matheson; Anna England; Helen Findlow; Xilian Bai; Raymond Borrow; Polly Burbidge; Emma Pearce; David Goldblatt; Elizbeth Miller

doi:10.1016/j.vaccine.2014.12.018

Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule

Shamez Ladhani^*
, Nicholas Andrews
, Pauline Waight
, Bassam Hallis
, Mary Matheson
, Anna England
, Helen Findlow
, Xilian Bai
, Raymond Borrow
, Polly Burbidge
, Emma Pearce
, David Goldblatt
, Elizbeth Miller

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

An open, non-randomised study was undertaken in England during 2011-12 to evaluate vaccine antibody responses in infants after completion of the routine primary infant immunisation schedule, which included two doses of meningococcal group C (MenC) conjugate (MCC) vaccine at 3 and 4 months. Any of the three licensed MCC vaccines could be used for either dose, depending on local availability. Healthy term infants registered at participating general practices (GPs) in Hertfordshire and Gloucestershire, UK, were recruited prospectively to provide a single blood sample four weeks after primary immunisation, which was administered by the GP surgery. Vaccination history was obtained at blood sampling. MenC serum bactericidal antibody (SBA) and IgG antibodies against Haemophilus influenzae b (Hib), pertussis toxin (PT), diphtheria toxoid (DT), tetanus toxoid (TT) and thirteen pneumococcal serotypes were analysed according to MCC vaccines received. MenC SBA responses differed significantly (P<. 0.001) according to MCC vaccine schedule as follows: MenC SBA geometric mean titres (GMTs) were significantly lower in infants receiving a diphtheria cross-reacting material-conjugated MCC (MCC-CRM) vaccine followed by TT-conjugated MCC (MCC-TT) vaccine (82.0; 95% CI, 39-173; n= 14) compared to those receiving two MCC-CRM (418; 95% CI, 325-537; n= 82), two MCC-TT (277; 95% CI, 223-344; n= 79) or MCC-TT followed by MCC-CRM (553; 95% CI, 322-949; n= 18). The same group also had the lowest Hib geometric mean concentrations (0.60. μg/mL, 0.27-1.34) compared to 1.85. μg/mL (1.23-2.78), 2.86. μg/mL (2.02-4.05) and 4.26. μg/mL (1.94-9.36), respectively. Our results indicate that MCC vaccines with different carrier proteins are not interchangeable. When several MCC vaccines are available, children requiring more than one dose should receive MCC vaccines with the same carrier protein or, alternatively, receive MCC-TT first wherever possible.

Original language	English
Pages (from-to)	648-655
Number of pages	8
Journal	Vaccine
Volume	33
Issue number	5
DOIs	https://doi.org/10.1016/j.vaccine.2014.12.018
Publication status	Published - 29 Jan 2015

Bibliographical note

Funding Information:
Conflicts of interest statement : Dr Ladhani has conducted clinical trials and received financial assistance to attend scientific conferences from vaccine manufacturers on behalf of St. George's University of London, but receives no personal remuneration. Professor Borrow, Dr Findlow and Dr Bai perform contract research for vaccine manufacturers on behalf of Public Health England, but receive no personal remuneration. Dr H. Findlow has received financial assistance from a vaccine manufacturer to attend a scientific conference. Professor Goldblatt has provided consultancy services for vaccine manufacturers and his institution has received grants from vaccine manufacturers for contract research. All other authors: no conflict. Funding : We thank the Research and Development Directorate of the United Kingdom Department of Health for funding the fieldwork of the study (grant number 039/0031 ). The funding body did not have any role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. The views expressed in the publication are those of the authors and not necessarily those of the Department of Health.

Publisher Copyright:
© 2014 Elsevier Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Carrier proteins
Conjugate vaccines
Interchangeability
Interference
Meningococcal capsular group C

Access to Document

10.1016/j.vaccine.2014.12.018

Cite this

Ladhani, S., Andrews, N., Waight, P., Hallis, B., Matheson, M., England, A., Findlow, H., Bai, X., Borrow, R., Burbidge, P., Pearce, E., Goldblatt, D., & Miller, E. (2015). Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule. Vaccine, 33(5), 648-655. https://doi.org/10.1016/j.vaccine.2014.12.018

@article{789fb4a93f7b4efa90e4f65e0a5dcf26,

title = "Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule",

abstract = "An open, non-randomised study was undertaken in England during 2011-12 to evaluate vaccine antibody responses in infants after completion of the routine primary infant immunisation schedule, which included two doses of meningococcal group C (MenC) conjugate (MCC) vaccine at 3 and 4 months. Any of the three licensed MCC vaccines could be used for either dose, depending on local availability. Healthy term infants registered at participating general practices (GPs) in Hertfordshire and Gloucestershire, UK, were recruited prospectively to provide a single blood sample four weeks after primary immunisation, which was administered by the GP surgery. Vaccination history was obtained at blood sampling. MenC serum bactericidal antibody (SBA) and IgG antibodies against Haemophilus influenzae b (Hib), pertussis toxin (PT), diphtheria toxoid (DT), tetanus toxoid (TT) and thirteen pneumococcal serotypes were analysed according to MCC vaccines received. MenC SBA responses differed significantly (P<. 0.001) according to MCC vaccine schedule as follows: MenC SBA geometric mean titres (GMTs) were significantly lower in infants receiving a diphtheria cross-reacting material-conjugated MCC (MCC-CRM) vaccine followed by TT-conjugated MCC (MCC-TT) vaccine (82.0; 95\% CI, 39-173; n= 14) compared to those receiving two MCC-CRM (418; 95\% CI, 325-537; n= 82), two MCC-TT (277; 95\% CI, 223-344; n= 79) or MCC-TT followed by MCC-CRM (553; 95\% CI, 322-949; n= 18). The same group also had the lowest Hib geometric mean concentrations (0.60. μg/mL, 0.27-1.34) compared to 1.85. μg/mL (1.23-2.78), 2.86. μg/mL (2.02-4.05) and 4.26. μg/mL (1.94-9.36), respectively. Our results indicate that MCC vaccines with different carrier proteins are not interchangeable. When several MCC vaccines are available, children requiring more than one dose should receive MCC vaccines with the same carrier protein or, alternatively, receive MCC-TT first wherever possible.",

keywords = "Carrier proteins, Conjugate vaccines, Interchangeability, Interference, Meningococcal capsular group C",

author = "Shamez Ladhani and Nicholas Andrews and Pauline Waight and Bassam Hallis and Mary Matheson and Anna England and Helen Findlow and Xilian Bai and Raymond Borrow and Polly Burbidge and Emma Pearce and David Goldblatt and Elizbeth Miller",

note = "Funding Information: Conflicts of interest statement : Dr Ladhani has conducted clinical trials and received financial assistance to attend scientific conferences from vaccine manufacturers on behalf of St. George's University of London, but receives no personal remuneration. Professor Borrow, Dr Findlow and Dr Bai perform contract research for vaccine manufacturers on behalf of Public Health England, but receive no personal remuneration. Dr H. Findlow has received financial assistance from a vaccine manufacturer to attend a scientific conference. Professor Goldblatt has provided consultancy services for vaccine manufacturers and his institution has received grants from vaccine manufacturers for contract research. All other authors: no conflict. Funding : We thank the Research and Development Directorate of the United Kingdom Department of Health for funding the fieldwork of the study (grant number 039/0031 ). The funding body did not have any role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. The views expressed in the publication are those of the authors and not necessarily those of the Department of Health. Publisher Copyright: {\textcopyright} 2014 Elsevier Ltd.",

year = "2015",

month = jan,

day = "29",

doi = "10.1016/j.vaccine.2014.12.018",

language = "English",

volume = "33",

pages = "648--655",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "5",

}

Ladhani, S , Andrews, N, Waight, P, Hallis, B , Matheson, M , England, A, Findlow, H, Bai, X , Borrow, R, Burbidge, P, Pearce, E, Goldblatt, D & Miller, E 2015, 'Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule', Vaccine, vol. 33, no. 5, pp. 648-655. https://doi.org/10.1016/j.vaccine.2014.12.018

TY - JOUR

T1 - Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule

AU - Ladhani, Shamez

AU - Andrews, Nicholas

AU - Waight, Pauline

AU - Hallis, Bassam

AU - Matheson, Mary

AU - England, Anna

AU - Findlow, Helen

AU - Bai, Xilian

AU - Borrow, Raymond

AU - Burbidge, Polly

AU - Pearce, Emma

AU - Goldblatt, David

AU - Miller, Elizbeth

N1 - Funding Information: Conflicts of interest statement : Dr Ladhani has conducted clinical trials and received financial assistance to attend scientific conferences from vaccine manufacturers on behalf of St. George's University of London, but receives no personal remuneration. Professor Borrow, Dr Findlow and Dr Bai perform contract research for vaccine manufacturers on behalf of Public Health England, but receive no personal remuneration. Dr H. Findlow has received financial assistance from a vaccine manufacturer to attend a scientific conference. Professor Goldblatt has provided consultancy services for vaccine manufacturers and his institution has received grants from vaccine manufacturers for contract research. All other authors: no conflict. Funding : We thank the Research and Development Directorate of the United Kingdom Department of Health for funding the fieldwork of the study (grant number 039/0031 ). The funding body did not have any role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. The views expressed in the publication are those of the authors and not necessarily those of the Department of Health. Publisher Copyright: © 2014 Elsevier Ltd.

PY - 2015/1/29

Y1 - 2015/1/29

N2 - An open, non-randomised study was undertaken in England during 2011-12 to evaluate vaccine antibody responses in infants after completion of the routine primary infant immunisation schedule, which included two doses of meningococcal group C (MenC) conjugate (MCC) vaccine at 3 and 4 months. Any of the three licensed MCC vaccines could be used for either dose, depending on local availability. Healthy term infants registered at participating general practices (GPs) in Hertfordshire and Gloucestershire, UK, were recruited prospectively to provide a single blood sample four weeks after primary immunisation, which was administered by the GP surgery. Vaccination history was obtained at blood sampling. MenC serum bactericidal antibody (SBA) and IgG antibodies against Haemophilus influenzae b (Hib), pertussis toxin (PT), diphtheria toxoid (DT), tetanus toxoid (TT) and thirteen pneumococcal serotypes were analysed according to MCC vaccines received. MenC SBA responses differed significantly (P<. 0.001) according to MCC vaccine schedule as follows: MenC SBA geometric mean titres (GMTs) were significantly lower in infants receiving a diphtheria cross-reacting material-conjugated MCC (MCC-CRM) vaccine followed by TT-conjugated MCC (MCC-TT) vaccine (82.0; 95% CI, 39-173; n= 14) compared to those receiving two MCC-CRM (418; 95% CI, 325-537; n= 82), two MCC-TT (277; 95% CI, 223-344; n= 79) or MCC-TT followed by MCC-CRM (553; 95% CI, 322-949; n= 18). The same group also had the lowest Hib geometric mean concentrations (0.60. μg/mL, 0.27-1.34) compared to 1.85. μg/mL (1.23-2.78), 2.86. μg/mL (2.02-4.05) and 4.26. μg/mL (1.94-9.36), respectively. Our results indicate that MCC vaccines with different carrier proteins are not interchangeable. When several MCC vaccines are available, children requiring more than one dose should receive MCC vaccines with the same carrier protein or, alternatively, receive MCC-TT first wherever possible.

AB - An open, non-randomised study was undertaken in England during 2011-12 to evaluate vaccine antibody responses in infants after completion of the routine primary infant immunisation schedule, which included two doses of meningococcal group C (MenC) conjugate (MCC) vaccine at 3 and 4 months. Any of the three licensed MCC vaccines could be used for either dose, depending on local availability. Healthy term infants registered at participating general practices (GPs) in Hertfordshire and Gloucestershire, UK, were recruited prospectively to provide a single blood sample four weeks after primary immunisation, which was administered by the GP surgery. Vaccination history was obtained at blood sampling. MenC serum bactericidal antibody (SBA) and IgG antibodies against Haemophilus influenzae b (Hib), pertussis toxin (PT), diphtheria toxoid (DT), tetanus toxoid (TT) and thirteen pneumococcal serotypes were analysed according to MCC vaccines received. MenC SBA responses differed significantly (P<. 0.001) according to MCC vaccine schedule as follows: MenC SBA geometric mean titres (GMTs) were significantly lower in infants receiving a diphtheria cross-reacting material-conjugated MCC (MCC-CRM) vaccine followed by TT-conjugated MCC (MCC-TT) vaccine (82.0; 95% CI, 39-173; n= 14) compared to those receiving two MCC-CRM (418; 95% CI, 325-537; n= 82), two MCC-TT (277; 95% CI, 223-344; n= 79) or MCC-TT followed by MCC-CRM (553; 95% CI, 322-949; n= 18). The same group also had the lowest Hib geometric mean concentrations (0.60. μg/mL, 0.27-1.34) compared to 1.85. μg/mL (1.23-2.78), 2.86. μg/mL (2.02-4.05) and 4.26. μg/mL (1.94-9.36), respectively. Our results indicate that MCC vaccines with different carrier proteins are not interchangeable. When several MCC vaccines are available, children requiring more than one dose should receive MCC vaccines with the same carrier protein or, alternatively, receive MCC-TT first wherever possible.

KW - Carrier proteins

KW - Conjugate vaccines

KW - Interchangeability

KW - Interference

KW - Meningococcal capsular group C

UR - https://www.scopus.com/pages/publications/84921059496

U2 - 10.1016/j.vaccine.2014.12.018

DO - 10.1016/j.vaccine.2014.12.018

M3 - Article

C2 - 25510388

AN - SCOPUS:84921059496

SN - 0264-410X

VL - 33

SP - 648

EP - 655

JO - Vaccine

JF - Vaccine

IS - 5

ER -

Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this